PTC THERAPEUTICS INC

Insider selling by Michael Schmertzler at PTC Therapeutics signals potential confidence issues amid a steep decline—watch Q3 earnings for a possible turnaround.

Mark Boulding’s recent buy‑sell of PTC Therapeutics shares shows insider confidence in the company’s long‑term value, offering a subtle boost for investors.